Outcome of myelodysplastic neoplasms with unrelated donor transplants: PTCY vs ATG (univariable)
| Variables . | Total . | PTCY . | ATG . | P value . |
|---|---|---|---|---|
| Patient number | 960 | 209 | 751 | |
| D28 neutrophil engraftment (95% CI) | 91% (89-93) | 85% (80-89) | 93% (91-94) | <.001 |
| D100 platelet engraftment (95% CI) | 89% (87-91) | 86% (82-91) | 90% (88-92) | <.001 |
| D100 primary graft failure | 3% (2-5) | 6% (3-9) | 3% (2-4) | .025 |
| 5-y OS | 51% (48-54) | 58% (50-65) | 49% (46-53) | .07 |
| 5-y PFS | 46% (42-49) | 53% (45-60) | 44% (40-48) | .043 |
| 5-y relapse/progression | 25% (22-28) | 22% (16-29) | 25% (22-29) | .3 |
| 5-y NRM | 30% (27-33) | 25% (19-31) | 31% (27-34) | .18 |
| D100 aGVHD (95% CI) | ||||
| aGVHD grade 2-4 | 28% (26-31) | 23% (17-29) | 30% (27-33) | .044 |
| aGVHD grade 3-4 | 12% (10-14) | 11% (7-16) | 13% (10-15) | .6 |
| 5-y cGVHD (95% CI) | ||||
| All | 38% (34-41) | 37% (30-44) | 38% (34-41) | .7 |
| Mild | 12% (10-15) | 16% (10-21) | 12% (9-14) | .15 |
| Moderate | 10% (8-12) | 12% (7-17) | 10% (7-12) | .4 |
| Severe | 7% (6-9) | 4% (1-7) | 8% (6-10) | .08 |
| 5-y cGVHD-free survival | 21% (18-23) | 24% (17-31) | 20% (17-23) | .07 |
| 5-y GRFS (95% CI) | 32% (29-35) | 36% (28-43) | 31% (27-34) | .18 |
| Variables . | Total . | PTCY . | ATG . | P value . |
|---|---|---|---|---|
| Patient number | 960 | 209 | 751 | |
| D28 neutrophil engraftment (95% CI) | 91% (89-93) | 85% (80-89) | 93% (91-94) | <.001 |
| D100 platelet engraftment (95% CI) | 89% (87-91) | 86% (82-91) | 90% (88-92) | <.001 |
| D100 primary graft failure | 3% (2-5) | 6% (3-9) | 3% (2-4) | .025 |
| 5-y OS | 51% (48-54) | 58% (50-65) | 49% (46-53) | .07 |
| 5-y PFS | 46% (42-49) | 53% (45-60) | 44% (40-48) | .043 |
| 5-y relapse/progression | 25% (22-28) | 22% (16-29) | 25% (22-29) | .3 |
| 5-y NRM | 30% (27-33) | 25% (19-31) | 31% (27-34) | .18 |
| D100 aGVHD (95% CI) | ||||
| aGVHD grade 2-4 | 28% (26-31) | 23% (17-29) | 30% (27-33) | .044 |
| aGVHD grade 3-4 | 12% (10-14) | 11% (7-16) | 13% (10-15) | .6 |
| 5-y cGVHD (95% CI) | ||||
| All | 38% (34-41) | 37% (30-44) | 38% (34-41) | .7 |
| Mild | 12% (10-15) | 16% (10-21) | 12% (9-14) | .15 |
| Moderate | 10% (8-12) | 12% (7-17) | 10% (7-12) | .4 |
| Severe | 7% (6-9) | 4% (1-7) | 8% (6-10) | .08 |
| 5-y cGVHD-free survival | 21% (18-23) | 24% (17-31) | 20% (17-23) | .07 |
| 5-y GRFS (95% CI) | 32% (29-35) | 36% (28-43) | 31% (27-34) | .18 |